ERBB2 and breast carcinoma: In the H-CSS cohort (Table 2), the analysis across breast cancer (BC) molecular subtypes (Luminal A, Luminal B, HER2-amplified, and basal/Triple-negative (TNEG); see “Methods”) showed a lower expression of miR-141-3p (p = 0.0306) and miR-200a-3p (p = 0.0381) in those tumors associated to more aggressive subtypes (e.g. LUMB, HER2-amplified and TNEG) Table 2).